Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INV 103

Drug Profile

INV 103

Alternative Names: ala-chaperonin-10; Ala-Cpn10; Chaperonin 10; Cpn 10; Heat shock protein 10 - Invion; HSP-10 - Invion; INV103; Recombinant Cpn 10; XToll

Latest Information Update: 13 Oct 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CBio
  • Developer CBio; Invion
  • Class Anti-inflammatories; Antirheumatics; Chaperonins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Autoimmune disorders

Highest Development Phases

  • Phase I/II Systemic lupus erythematosus
  • No development reported Multiple sclerosis; Plaque psoriasis; Rheumatoid arthritis
  • Discontinued Ulcerative colitis

Most Recent Events

  • 14 Nov 2014 HSP 10 is available for licensing as of 14 Nov 2014. http://inviongroup.com
  • 01 Jul 2013 No development reported - Phase-II for Multiple sclerosis in Australia (IV)
  • 01 Jul 2013 No development reported - Phase-II for Plaque psoriasis in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top